Media stories about BioLife Solutions (NASDAQ:BLFS) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioLife Solutions earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.8446846147706 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Several research firms recently issued reports on BLFS. Maxim Group set a $9.00 price target on shares of BioLife Solutions and gave the stock a “buy” rating in a report on Monday, April 30th. B. Riley began coverage on shares of BioLife Solutions in a report on Thursday, June 7th. They set a “buy” rating and a $14.00 price target for the company. Northland Securities reissued a “buy” rating and set a $18.00 price target on shares of BioLife Solutions in a report on Friday. Finally, ValuEngine raised shares of BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Friday, May 4th.

NASDAQ BLFS traded down $0.14 during trading hours on Friday, hitting $19.72. 304,568 shares of the stock were exchanged, compared to its average volume of 350,231. The stock has a market capitalization of $280.93 million, a P/E ratio of -93.90 and a beta of 0.64. BioLife Solutions has a 12-month low of $3.60 and a 12-month high of $22.86.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. The firm had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.20 million. BioLife Solutions had a net margin of 1.76% and a return on equity of 2.86%. equities research analysts predict that BioLife Solutions will post 0.14 earnings per share for the current year.

In other BioLife Solutions news, CFO Greef Roderick De sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 18th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the transaction, the chief financial officer now directly owns 24,583 shares in the company, valued at $491,660. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Rice sold 12,540 shares of the company’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $8.65, for a total transaction of $108,471.00. Following the transaction, the chief executive officer now owns 152,057 shares in the company, valued at $1,315,293.05. The disclosure for this sale can be found here. Insiders have sold 599,478 shares of company stock valued at $6,925,968 over the last three months. 38.50% of the stock is currently owned by corporate insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Recommended Story: Google Finance Portfolio Workaround

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.